Alzamend Neuro, Inc. — Form 10-K
Filed July 22, 2026 · analyzed by the Periodic Agent
10-K
▼ Likely negative
significance 82/100
What the filing says
As of July 22, 2026, Alzamend Neuro had 4,791,525 shares of common stock outstanding (par value $0.0001) with 300M shares authorized. The company's independent auditor (Haskell White LLP) issued a going concern opinion, expressing substantial doubt about the company's ability to continue operations. Capital structure includes 10M authorized preferred shares.
Why this rating
Going concern warning is material red flag for viability; at $9.6M market cap, any operational failure threatens existence. Not yet bankruptcy but severe risk signal.
See more from July 22, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.